{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-030023","form_type":"8-K","ticker":"SFES","cik":"0000086115","company_name":"SAFEGUARD SCIENTIFICS INC","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.177524+00:00","generated_at":"2026-06-09T01:24:13.601717+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Safeguard Scientifics Q3 net income $0.9M, vs loss $3.2M; cash $15.7M","bullets":["Q3 net income $0.9M ($0.06 diluted EPS) vs net loss $3.2M ($0.19 loss) in Q3 2022.","9M net loss narrowed to $5.4M ($0.33 loss) from $9.4M ($0.57 loss) year earlier.","Cash and equivalents $15.7M; carrying value of ownership interests $14.8M (cost $122.8M).","InfoBionic recap reduced ownership to ~5% with $1.7M non-cash gain; Trice Medical recap resulted in de minimis stake.","Aggregate trailing 12-month revenue of six portfolio companies $96M, up 10.3% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-030023","json":"https://secwatch.observer/filing/0001437749-23-030023.json","markdown":"https://secwatch.observer/filing/0001437749-23-030023.md","text":"https://secwatch.observer/filing/0001437749-23-030023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/86115/000143774923030023/0001437749-23-030023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/86115/000143774923030023/sfe20231102_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T01:24:13.601717+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"faf29b4370b31050cebba42426e7014f11c77ab1","claim":"SAFEGUARD SCIENTIFICS INC reported the three and nine months ended September 30, 2023 results: net income Net income for the three months ended September 30, 2023 was $0.9 million, or $0.06 per basic and fully diluted share, a.","evidence_excerpt":"o Net income for the three months ended September 30, 2023 was $0.9 million, or $0.06 per basic and fully diluted share, as compared with a net loss of $3.2 million, or $0.19 per basic and fully diluted share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/86115/000143774923030023/0001437749-23-030023-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2023"},{"label":"Net income","value":"Net income for the three months ended September 30, 2023 was $0.9 million, or $0.06 per basic and fully diluted share, a"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}